Biomimetic nano-NOS mediated local NO release for inhibiting cancer-associated platelet activation and disrupting tumor vascular barriers

Ma, Zhanhong; Shi, Liyi; Ke, Yanxiong; Wang, H.; Chen, Runhai; Xiang, Zehong; Xie, Zhigang; Shi, Qiang; Yin, Jinghua

doi:10.1016/j.biomaterials.2020.120141

Cited by 38 publications

(28 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al have fabricated the photosensitizer chlorin e6 (Ce6), and the chemotherapy drug paclitaxel (PTX) co-loaded human serum albumin (HSA) nanoparticles with cRGDyK peptide modification ( Figure 2B ), which were able to target tumor angiogenic endothelium overexpressing α v β 3 -integrin and exhibited significant antitumor efficacy due to the combined photodynamic/chemotherapy ( Chen et al, 2015 ). Ma et al (2020) have presented an antiplatelet strategy based on erythrocyte membrane-coated bovine serum albumin (BSA) nanoparticles that co-load L-Arginine (LA) and photosensitizer IR783. They first used BSA as the scaffold to co-load LA and IR783, then the obtained drug-loading albumin nanoparticles were coated with red blood cell (RBC) membrane, and finally, the cRGD peptides were integrated into the lipid bilayer of RBC membrane to get the cRGD peptides conjugated and erythrocyte membrane-coated BSA nanoparticles with co-loading of LA and IR783.…”

Section: Different Types Of Serum Albumin-based Nanovehiclesmentioning

confidence: 99%

Recent Advancements in Serum Albumin-Based Nanovehicles Toward Potential Cancer Diagnosis and Therapy

Shen

Liu

et al. 2021

Front. Chem.

View full text Add to dashboard Cite

Recently, drug delivery vehicles based on nanotechnology have significantly attracted the attention of researchers in the field of nanomedicine since they can achieve ideal drug release and biodistribution. Among the various organic or inorganic materials that used to prepare drug delivery vehicles for effective cancer treatment, serum albumin-based nanovehicles have been widely developed and investigated due to their prominent superiorities, including good biocompatibility, high stability, nontoxicity, non-immunogenicity, easy preparation, and functionalization, allowing them to be promising candidates for cancer diagnosis and therapy. This article reviews the recent advances on the applications of serum albumin-based nanovehicles in cancer diagnosis and therapy. We first introduce the essential information of bovine serum albumin (BSA) and human serum albumin (HSA), and discuss their drug loading strategies. We then discuss the different types of serum albumin-based nanovehicles including albumin nanoparticles, surface-functionalized albumin nanoparticles, and albumin nanocomplexes. Moreover, after briefly discussing the application of serum albumin-based nanovehicles used as the nanoprobes in cancer diagnosis, we also describe the serum albumin-based nanovehicle-assisted cancer theranostics, involving gas therapy, chemodynamic therapy (CDT), phototherapy (PTT/PDT), sonodynamic therapy (SDT), and other therapies as well as cancer imaging. Numerous studies cited in our review show that serum albumin-based nanovehicles possess a great potential in cancer diagnostic and therapeutic applications.

show abstract

Section: Different Types Of Serum Albumin-based Nanovehiclesmentioning

confidence: 99%

Recent Advancements in Serum Albumin-Based Nanovehicles Toward Potential Cancer Diagnosis and Therapy

Shen

Liu

et al. 2021

Front. Chem.

View full text Add to dashboard Cite

show abstract

“…Nitric oxide (NO) is another signal molecule exhibiting multiple antitumor activities [ 228 ]. Therefore, one study incorporated a GSH-sensitive NO donor into the iron-based nanoscale coordination polymer (NCP) [ 229 ].…”

Section: Fenton and Fenton-like Reactions-mediated Combination Therapymentioning

confidence: 99%

Chemodynamic nanomaterials for cancer theranostics

et al. 2021

View full text Add to dashboard Cite

It is of utmost urgency to achieve effective and safe anticancer treatment with the increasing mortality rate of cancer. Novel anticancer drugs and strategies need to be designed for enhanced therapeutic efficacy. Fenton- and Fenton-like reaction-based chemodynamic therapy (CDT) are new strategies to enhance anticancer efficacy due to their capacity to generate reactive oxygen species (ROS) and oxygen (O2). On the one hand, the generated ROS can damage the cancer cells directly. On the other hand, the generated O2 can relieve the hypoxic condition in the tumor microenvironment (TME) which hinders efficient photodynamic therapy, radiotherapy, etc. Therefore, CDT can be used together with many other therapeutic strategies for synergistically enhanced combination therapy. The antitumor applications of Fenton- and Fenton-like reaction-based nanomaterials will be discussed in this review, including: (iþ) producing abundant ROS in-situ to kill cancer cells directly, (ii) enhancing therapeutic efficiency indirectly by Fenton reaction-mediated combination therapy, (iii) diagnosis and monitoring of cancer therapy. These strategies exhibit the potential of CDT-based nanomaterials for efficient cancer therapy.

show abstract

“…110 This can be counterbalanced by the very short half-life of NO and consequently, its limited action zone. 104 In parallel, after their parenteral administration, which is the most studied administration route, NP rapidly interact with immune cells and are distributed to reticuloendothelial organs (liver, spleen, lungs). 111 Combined, the properties of NO and NP explain why, besides general indicators of toxicity (body weight, general behavior of animals), other physiological and biochemical parameters must be explored to assess the potential systemic toxicity of the nanoarchitectures.…”

Section: In Vivo Biocompatibility Of No-releasing Np or No-producing Npmentioning

confidence: 99%

Recent progress in the toxicity of nitric oxide-releasing nanomaterials

et al. 2021

View full text Add to dashboard Cite

show abstract

Biomimetic nano-NOS mediated local NO release for inhibiting cancer-associated platelet activation and disrupting tumor vascular barriers

Cited by 38 publications

References 48 publications

Recent Advancements in Serum Albumin-Based Nanovehicles Toward Potential Cancer Diagnosis and Therapy

Recent Advancements in Serum Albumin-Based Nanovehicles Toward Potential Cancer Diagnosis and Therapy

Chemodynamic nanomaterials for cancer theranostics

Recent progress in the toxicity of nitric oxide-releasing nanomaterials

Contact Info

Product

Resources

About